mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease

Alzheimer's and Dementia

Volumn 13, Issue 2, 2017, Pages 152-167

  Norambuena, Andrés ^a   Wallrabe, Horst ^a   McMahon, Lloyd ^b   Silva, Antonia ^a   Swanson, Eric ^a   Khan, Shahzad S ^a   Baerthlein, Daniel ^a   Kodis, Erin ^a   Oddo, Salvatore ^c   Mandell, James W ^b   Bloom, George S ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid oligomers; Cell cycle reentry; Diabetes; Insulin; Rac1; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; OLIGOMER; TAU PROTEIN; AMYLOID BETA PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAPT PROTEIN, HUMAN; MAPT PROTEIN, MOUSE;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; LYSOSOME; MOLECULAR PATHOLOGY; MOUSE; NERVE CELL CULTURE; NERVE CELL NECROSIS; NEURONAL CELL CYCLE REENTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; AGED; ANIMAL; BRAIN CORTEX; CELL CULTURE; CELL CYCLE; GENETICS; KNOCKOUT MOUSE; METABOLISM; MIDDLE AGED; NERVE CELL; NORMOTENSIVE HYDROCEPHALUS; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELL CYCLE; CELL MEMBRANE; CELLS, CULTURED; CEREBRAL CORTEX; HUMANS; HYDROCEPHALUS, NORMAL PRESSURE; INSULIN; LYSOSOMES; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 2; MICE, KNOCKOUT; MIDDLE AGED; NEURONS; TAU PROTEINS;

EID: 85005981036     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.08.015     Document Type: Article

References (63)

1. [1] Huang, Y., Mucke, L., Alzheimer mechanisms and therapeutic strategies. Cell 148 (2012), 1204–1222.
2. [2] Bloom, G.S., Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71 (2014), 505–508.
3. [3] de la Monte, S.M., Type 3 diabetes is sporadic Alzheimer's disease: mini-review. Eur Neuropsychopharmacol 24 (2014), 1954–1960.
4. [4] Steen, E., Terry, B.M., Rivera, E.J., Cannon, J.L., Neely, T.R., Tavares, R., et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease—is this type 3 diabetes?. J Alzheimers Dis 7 (2005), 63–80.
5. [5] West, M.J., Coleman, P.D., Flood, D.G., Troncoso, J.C., Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 344 (1994), 769–772.
6. [6] Bussiere, T., Giannakopoulos, P., Bouras, C., Perl, D.P., Morrison, J.H., Hof, P.R., Progressive degeneration of nonphosphorylated neurofilament protein-enriched pyramidal neurons predicts cognitive impairment in Alzheimer's disease: stereologic analysis of prefrontal cortex area 9. J Comp Neurol 463 (2003), 281–302.
7. [7] Arendt, T., Bruckner, M.K., Mosch, B., Losche, A., Selective cell death of hyperploid neurons in Alzheimer's disease. Am J Pathol 177 (2010), 15–20.
8. [8] Herrup, K., Yang, Y., Cell cycle regulation in the postmitotic neuron: oxymoron or new biology?. Nat Rev Neurosci 8 (2007), 368–378.
9. [9] Yang, Y., Mufson, E.J., Herrup, K., Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci 23 (2003), 2557–2563.
10. [10] Seward, M.E., Swanson, E., Norambuena, A., Reimann, A., Cochran, J.N., Li, R., et al. Amyloid-beta signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease. J Cell Sci 126 (2013), 1278–1286.
11. [11] Varvel, N.H., Bhaskar, K., Patil, A.R., Pimplikar, S.W., Herrup, K., Lamb, B.T., Abeta oligomers induce neuronal cell cycle events in Alzheimer's disease. J Neurosci 28 (2008), 10786–10793.
12. [12] Khurana, V., Lu, Y., Steinhilb, M.L., Oldham, S., Shulman, J.M., Feany, M.B., TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr Biol 16 (2006), 230–241.
13. [13] Menon, S., Dibble, C.C., Talbott, G., Hoxhaj, G., Valvezan, A.J., Takahashi, H., et al. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell 156 (2014), 771–785.
14. [14] Saci, A., Cantley, L.C., Carpenter, C.L., Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Mol Cell 42 (2011), 50–61.
15. [15] Liu, P., Gan, W., Inuzuka, H., Lazorchak, A.S., Gao, D., Arojo, O., et al. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol 15 (2013), 1340–1350.
16. [16] Xie, J., Proud, C.G., Crosstalk between mTOR complexes. Nat Cell Biol 15 (2013), 1263–1265.
17. [17] Oddo, S., The role of mTOR signaling in Alzheimer disease. Front Biosci 4 (2012), 941–952.
18. [18] Caccamo, A., Magri, A., Medina, D.X., Wisely, E.V., Lopez-Aranda, M.F., Silva, A.J., et al. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. Aging Cell 12 (2013), 370–380.
19. [19] Caccamo, A., Majumder, S., Richardson, A., Strong, R., Oddo, S., Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and tau: effects on cognitive impairments. J Biol Chem 285 (2010), 13107–13120.
20. [20] Dawson, H.N., Ferreira, A., Eyster, M.V., Ghoshal, N., Binder, L.I., Vitek, M.P., Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci 114 (2001), 1179–1187.
21. [21] Dunn, K.W., Kamocka, M.M., McDonald, J.H., A practical guide to evaluating colocalization in biological microscopy. Am J Physiol Cell Physiol 300 (2011), C723–C742.
22. [22] Oddo, S., Caccamo, A., Shepherd, J.D., Murphy, M.P., Golde, T.E., Kayed, R., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aß and synaptic dysfunction. Neuron 39 (2003), 409–421.
23. [23] Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., et al. Correlative memory deficits, Aß elevation, and amyloid plaques in transgenic mice. Science 274 (1996), 99–102.
24. [24] Caccamo, A., De Pinto, V., Messina, A., Branca, C., Oddo, S., Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. J Neurosci 34 (2014), 7988–7998.
25. [25] Ma, X.M., Blenis, J., Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10 (2009), 307–318.
26. [26] Gerdes, J., Schwab, U., Lemke, H., Stein, H., Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31 (1983), 13–20.
27. [27] Demetriades, C., Doumpas, N., Teleman, A.A., Regulation of TORC1 in response to amino acid starvation via lysosomal recruitment of TSC2. Cell 156 (2014), 786–799.
28. [28] Zoncu, R., Efeyan, A., Sabatini, D.M., mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12 (2011), 21–35.
29. [29] Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A.L., Nada, S., Sabatini, D.M., Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141 (2010), 290–303.
30. [30] Gao, Y., Dickerson, J.B., Guo, F., Zheng, J., Zheng, Y., Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A 101 (2004), 7618–7623.
31. [31] Bodrikov, V., Sytnyk, V., Leshchyns'ka, I., den Hertog, J., Schachner, M., NCAM induces CaMKIIalpha-mediated RPTPalpha phosphorylation to enhance its catalytic activity and neurite outgrowth. J Cell Biol 182 (2008), 1185–1200.
32. [32] Northup, J.K., Sternweis, P.C., Smigel, M.D., Schleifer, L.S., Ross, E.M., Gilman, A.G., Purification of the regulatory component of adenylate cyclase. Proc Natl Acad Sci U S A 77 (1980), 6516–6520.
33. [33] Toschi, A., Lee, E., Xu, L., Garcia, A., Gadir, N., Foster, D.A., Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol 29 (2009), 1411–1420.
34. [34] Green, M., Loewenstein, P.M., Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55 (1988), 1179–1188.
35. [35] Navarro-Lerida, I., Sanchez-Perales, S., Calvo, M., Rentero, C., Zheng, Y., Enrich, C., et al. A palmitoylation switch mechanism regulates Rac1 function and membrane organization. EMBO J 31 (2012), 534–551.
36. [36] del Pozo, M.A., Alderson, N.B., Kiosses, W.B., Chiang, H.H., Anderson, R.G., Schwartz, M.A., Integrins regulate Rac targeting by internalization of membrane domains. Science 303 (2004), 839–842.
37. [37] Moissoglu, K., Kiessling, V., Wan, C., Hoffman, B.D., Norambuena, A., Tamm, L.K., et al. Regulation of Rac1 translocation and activation by membrane domains and their boundaries. J Cell Sci 127 (2014), 2565–2576.
38. [38] Lingwood, D., Simons, K., Lipid rafts as a membrane-organizing principle. Science 327 (2010), 46–50.
39. [39] Bar-Peled, L., Chantranupong, L., Cherniack, A.D., Chen, W.W., Ottina, K.A., Grabiner, B.C., et al. A tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 340 (2013), 1100–1106.
40. [40] Grundke-Iqbal, I., Iqbal, K., Tung, Y.C., Quinlan, M., Wisniewski, H.M., Binder, L.I., Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83 (1986), 4913–4917.
41. [41] Noble, W., Hanger, D.P., Miller, C.C., Lovestone, S., The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol, 4, 2013, 83.
42. [42] Alonso, A.D., Di Clerico, J., Li, B., Corbo, C.P., Alaniz, M.E., Grundke-Iqbal, I., et al. Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. J Biol Chem 285 (2010), 30851–30860.
43. 262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 11 (1993), 153–163.
44. [44] Fath, T., Eidenmuller, J., Brandt, R., Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease. J Neurosci 22 (2002), 9733–9741.
45. [45] Gauthier-Kemper, A., Weissmann, C., Golovyashkina, N., Sebo-Lemke, Z., Drewes, G., Gerke, V., et al. The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner. J Cell Biol 192 (2011), 647–661.
46. [46] Pei, J.J., Bjorkdahl, C., Zhang, H., Zhou, X., Winblad, B., p70 S6 kinase and tau in Alzheimer's disease. J Alzheimers Dis 14 (2008), 385–392.
47. [47] Wilcock, D.M., Lewis, M.R., Van Nostrand, W.E., Davis, J., Previti, M.L., Gharkholonarehe, N., et al. Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J Neurosci 28 (2008), 1537–1545.
48. [48] Bomfim, T.R., Forny-Germano, L., Sathler, L.B., Brito-Moreira, J., Houzel, J.C., Decker, H., et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers. J Clin Invest 122 (2012), 1339–1353.
49. [49] De Felice, F.G., Lourenco, M.V., Ferreira, S.T., How does brain insulin resistance develop in Alzheimer's disease?. Alzheimers Dement 10 (2014), S26–S32.
50. [50] Talbot, K., Wang, H.Y., Kazi, H., Han, L.Y., Bakshi, K.P., Stucky, A., et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122 (2012), 1316–1338.
51. [51] Bhaskar, K., Maphis, N., Xu, G., Varvel, N.H., Kokiko-Cochran, O.N., Weick, J.P., et al. Microglial derived tumor necrosis factor-alpha drives Alzheimer's disease-related neuronal cell cycle events. Neurobiol Dis 62 (2014), 273–285.
52. [52] Williamson, R., Usardi, A., Hanger, D.P., Anderton, B.H., Membrane-bound beta-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism. FASEB J 22 (2008), 1552–1559.
53. [53] Partovian, C., Ju, R., Zhuang, Z.W., Martin, K.A., Simons, M., Syndecan-4 regulates subcellular localization of mTOR Complex2 and Akt activation in a PKCalpha-dependent manner in endothelial cells. Mol Cell 32 (2008), 140–149.
54. [54] Takemoto-Kimura, S., Ageta-Ishihara, N., Nonaka, M., Adachi-Morishima, A., Mano, T., Okamura, M., et al. Regulation of dendritogenesis via a lipid-raft-associated Ca2+/calmodulin-dependent protein kinase CLICK-III/CaMKIgamma. Neuron 54 (2007), 755–770.
55. [55] Vang, T., Torgersen, K.M., Sundvold, V., Saxena, M., Levy, F.O., Skalhegg, B.S., et al. Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J Exp Med 193 (2001), 497–507.
56. [56] Santuccione, A., Sytnyk, V., Leshchyns'ka, I., Schachner, M., Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate p59fyn and to enhance neurite outgrowth. J Cell Biol 169 (2005), 341–354.
57. [57] Smart, E.J., Ying, Y.S., Mineo, C., Anderson, R.G., A detergent-free method for purifying caveolae membrane from tissue culture cells. Proc Natl Acad Sci U S A 92 (1995), 10104–10108.
58. [58] Noda, T., Ohsumi, Y., Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem 273 (1998), 3963–3966.
59. [59] Majumder, S., Richardson, A., Strong, R., Oddo, S., Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One, 6, 2011, e25416.
60. [60] Lee, G., Thangavel, R., Sharma, V.M., Litersky, J.M., Bhaskar, K., Fang, S.M., et al. Phosphorylation of tau by fyn: implications for Alzheimer's disease. J Neurosci 24 (2004), 2304–2312.
61. [61] De Meyer, G., Shapiro, F., Vanderstichele, H., Vanmechelen, E., Engelborghs, S., De Deyn, P.P., et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67 (2010), 949–956.
62. [62] Li, J., Kim, S.G., Blenis, J., Rapamycin: one drug, many effects. Cell Metab 19 (2014), 373–379.
63. [63] Roberson, E.D., Scearce-Levie, K., Palop, J.J., Yan, F., Cheng, I.H., Wu, T., et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316 (2007), 750–754.